The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.

Sverre E. Kjeldsen, Paulette A. Lyle, Jorge Kizer, Björn Dahlöf, Richard B. Devereux, Stevo Julius, Gareth Beevers, Ulf de Faire, Frej Fyhrquist, Hans Ibsen, Krister Kristianson, Ole Lederballe-Pedersen, Lars H. Lindholm, Markku S. Nieminen, Per Omvik, Suzanne Oparil, Steven M. Snapinn, Katherine E. Harris, Hans Wedel

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH). Patients aged 55-80 years with blood pressures 160-200/<90 mm Hg were followed for a mean of 4.7 years. Blood pressure was similarly reduced in the losartan (n=660) and atenolol (n=666) ISH groups. There were 88 (6.6%) patients who experienced a stroke, 18 of which were fatal. Of patients experiencing strokes, 72.7% had an ischemic stroke. ISH patients in LIFE compared to the non-ISH group had a higher incidence of any stroke and embolic stroke, and similar incidences of fatal, atherosclerotic, and hemorrhagic/other strokes. The incidence of any stroke (40% risk reduction [RR], p=0.02), fatal stroke (70% RR, p=0.035), and atherothrombotic stroke (45% RR, p=0.022) was significantly lower in losartan-treated compared to the atenolol-treated patients. The 36% RR for embolic strokes in the losartan group was not statistically significantly (p=0.33) different from the atenolol group. These data suggest that losartan-based treatment is more effective than an atenolol-based treatment for patients with ISH and a high risk for stroke.

Original languageEnglish (US)
Pages (from-to)152-158
Number of pages7
JournalJournal of clinical hypertension (Greenwich, Conn.)
Volume7
Issue number3
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Atenolol
Losartan
Left Ventricular Hypertrophy
Stroke
Hypertension
Risk Reduction Behavior
Incidence
Myocardial Infarction
Blood Pressure
Antihypertensive Agents
Therapeutics
Morbidity

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. / Kjeldsen, Sverre E.; Lyle, Paulette A.; Kizer, Jorge; Dahlöf, Björn; Devereux, Richard B.; Julius, Stevo; Beevers, Gareth; de Faire, Ulf; Fyhrquist, Frej; Ibsen, Hans; Kristianson, Krister; Lederballe-Pedersen, Ole; Lindholm, Lars H.; Nieminen, Markku S.; Omvik, Per; Oparil, Suzanne; Snapinn, Steven M.; Harris, Katherine E.; Wedel, Hans.

In: Journal of clinical hypertension (Greenwich, Conn.), Vol. 7, No. 3, 03.2005, p. 152-158.

Research output: Contribution to journalArticle

Kjeldsen, SE, Lyle, PA, Kizer, J, Dahlöf, B, Devereux, RB, Julius, S, Beevers, G, de Faire, U, Fyhrquist, F, Ibsen, H, Kristianson, K, Lederballe-Pedersen, O, Lindholm, LH, Nieminen, MS, Omvik, P, Oparil, S, Snapinn, SM, Harris, KE & Wedel, H 2005, 'The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.', Journal of clinical hypertension (Greenwich, Conn.), vol. 7, no. 3, pp. 152-158.
Kjeldsen, Sverre E. ; Lyle, Paulette A. ; Kizer, Jorge ; Dahlöf, Björn ; Devereux, Richard B. ; Julius, Stevo ; Beevers, Gareth ; de Faire, Ulf ; Fyhrquist, Frej ; Ibsen, Hans ; Kristianson, Krister ; Lederballe-Pedersen, Ole ; Lindholm, Lars H. ; Nieminen, Markku S. ; Omvik, Per ; Oparil, Suzanne ; Snapinn, Steven M. ; Harris, Katherine E. ; Wedel, Hans. / The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. In: Journal of clinical hypertension (Greenwich, Conn.). 2005 ; Vol. 7, No. 3. pp. 152-158.
@article{00854dac376f4f389393e94320faab90,
title = "The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.",
abstract = "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH). Patients aged 55-80 years with blood pressures 160-200/<90 mm Hg were followed for a mean of 4.7 years. Blood pressure was similarly reduced in the losartan (n=660) and atenolol (n=666) ISH groups. There were 88 (6.6{\%}) patients who experienced a stroke, 18 of which were fatal. Of patients experiencing strokes, 72.7{\%} had an ischemic stroke. ISH patients in LIFE compared to the non-ISH group had a higher incidence of any stroke and embolic stroke, and similar incidences of fatal, atherosclerotic, and hemorrhagic/other strokes. The incidence of any stroke (40{\%} risk reduction [RR], p=0.02), fatal stroke (70{\%} RR, p=0.035), and atherothrombotic stroke (45{\%} RR, p=0.022) was significantly lower in losartan-treated compared to the atenolol-treated patients. The 36{\%} RR for embolic strokes in the losartan group was not statistically significantly (p=0.33) different from the atenolol group. These data suggest that losartan-based treatment is more effective than an atenolol-based treatment for patients with ISH and a high risk for stroke.",
author = "Kjeldsen, {Sverre E.} and Lyle, {Paulette A.} and Jorge Kizer and Bj{\"o}rn Dahl{\"o}f and Devereux, {Richard B.} and Stevo Julius and Gareth Beevers and {de Faire}, Ulf and Frej Fyhrquist and Hans Ibsen and Krister Kristianson and Ole Lederballe-Pedersen and Lindholm, {Lars H.} and Nieminen, {Markku S.} and Per Omvik and Suzanne Oparil and Snapinn, {Steven M.} and Harris, {Katherine E.} and Hans Wedel",
year = "2005",
month = "3",
language = "English (US)",
volume = "7",
pages = "152--158",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.

AU - Kjeldsen, Sverre E.

AU - Lyle, Paulette A.

AU - Kizer, Jorge

AU - Dahlöf, Björn

AU - Devereux, Richard B.

AU - Julius, Stevo

AU - Beevers, Gareth

AU - de Faire, Ulf

AU - Fyhrquist, Frej

AU - Ibsen, Hans

AU - Kristianson, Krister

AU - Lederballe-Pedersen, Ole

AU - Lindholm, Lars H.

AU - Nieminen, Markku S.

AU - Omvik, Per

AU - Oparil, Suzanne

AU - Snapinn, Steven M.

AU - Harris, Katherine E.

AU - Wedel, Hans

PY - 2005/3

Y1 - 2005/3

N2 - The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH). Patients aged 55-80 years with blood pressures 160-200/<90 mm Hg were followed for a mean of 4.7 years. Blood pressure was similarly reduced in the losartan (n=660) and atenolol (n=666) ISH groups. There were 88 (6.6%) patients who experienced a stroke, 18 of which were fatal. Of patients experiencing strokes, 72.7% had an ischemic stroke. ISH patients in LIFE compared to the non-ISH group had a higher incidence of any stroke and embolic stroke, and similar incidences of fatal, atherosclerotic, and hemorrhagic/other strokes. The incidence of any stroke (40% risk reduction [RR], p=0.02), fatal stroke (70% RR, p=0.035), and atherothrombotic stroke (45% RR, p=0.022) was significantly lower in losartan-treated compared to the atenolol-treated patients. The 36% RR for embolic strokes in the losartan group was not statistically significantly (p=0.33) different from the atenolol group. These data suggest that losartan-based treatment is more effective than an atenolol-based treatment for patients with ISH and a high risk for stroke.

AB - The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study reported that a losartan-based antihypertensive regimen reduced cardiovascular morbidity and mortality (composite of cardiovascular death, stroke, and myocardial infarction) more than therapy based on atenolol in patients with left ventricular hypertrophy and isolated systolic hypertension (ISH). Patients aged 55-80 years with blood pressures 160-200/<90 mm Hg were followed for a mean of 4.7 years. Blood pressure was similarly reduced in the losartan (n=660) and atenolol (n=666) ISH groups. There were 88 (6.6%) patients who experienced a stroke, 18 of which were fatal. Of patients experiencing strokes, 72.7% had an ischemic stroke. ISH patients in LIFE compared to the non-ISH group had a higher incidence of any stroke and embolic stroke, and similar incidences of fatal, atherosclerotic, and hemorrhagic/other strokes. The incidence of any stroke (40% risk reduction [RR], p=0.02), fatal stroke (70% RR, p=0.035), and atherothrombotic stroke (45% RR, p=0.022) was significantly lower in losartan-treated compared to the atenolol-treated patients. The 36% RR for embolic strokes in the losartan group was not statistically significantly (p=0.33) different from the atenolol group. These data suggest that losartan-based treatment is more effective than an atenolol-based treatment for patients with ISH and a high risk for stroke.

UR - http://www.scopus.com/inward/record.url?scp=20644466411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20644466411&partnerID=8YFLogxK

M3 - Article

C2 - 15785156

AN - SCOPUS:20644466411

VL - 7

SP - 152

EP - 158

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 3

ER -